Review papers with raw data transparency

• HTS (CETSA) identified small molecules that stabilize TFAM in cells and increase TFAM protein levels and mtDNA copy number (lead chemotype: arylsulfonamides; compound 2 and analogs) Astellas preprint
• These TFAM activators blunt TNFα-induced mtDNA escape → cGAS-STING → ISG signaling (measured by CXCL10 AlphaLISA and ISRE luciferase) and reduce cytosolic mtDNA (compound 3) Astellas preprint - ISG assays
• Functional benefits reported: increased ATP in MELAS cybrids, decreased fibrotic markers in SSc fibroblasts, increased Treg suppressive capacity — all in vitro (no in vivo data) Astellas preprint - disease models

Figure: dose-response potency in the ISRE assay (TNFα-stimulated THP-1-Dual); note sub-micromolar IC50 for MTC-0276 (≈0.93 µM) indicating tractable potency within lead-like space reported by authors ISRE IC50 table

• Solid
  • Orthogonal phenotypes: TFAM protein increases (WB/HiBiT) and mtDNA copy-number increases (ΔΔCT qPCR) co-occur with suppression of ISG readouts (CXCL10, ISRE) — consistent and observed across multiple cell lines and assays Concordant TFAM/protein/mtDNA/ISG data
  • TFAM siRNA attenuates the ability of compounds 2/3 to suppress ISRE, supporting TFAM dependence for those compounds (attenuation, not full abolition) TFAM knockdown dependence
• Weak / missing
  • No direct biochemical binding data: authors used CETSA (in-cell thermal stabilization) and functional readouts but did not show purified TFAM–ligand binding (SPR, ITC, MST) or co-crystal structures to prove direct interaction — a central blindspot for a claimed TFAM activator mechanism No direct binding data reported
  • Lack of in vitro TFAM functional assay data: TFAM is a DNA-binding/packaging protein; no experiments showed compound effects on TFAM–DNA affinity, nucleoid compaction, Lon protease turnover in vitro, or changes in TFAM post-translational modification — mechanistic gap (though prior TMP paper shows small molecules can protect TFAM from Lon) TMP binds TFAM and blocks degradation
  • Specificity and off-target profiling limited: no proteome-wide CETSA-MS or chemoproteomics shown; compound 15 shows ISG suppression without TFAM protein increase, indicating off-target or parallel mechanisms; absence of kinase/protease panel or mitochondrial off-target profiling leaves safety/interpretation uncertainty.
  • No in vivo efficacy, PK/ADME, or toxicity data: all disease-relevant claims are cellular; in vivo translation may be limited by mitochondrial delivery, metabolism, and TFAM tissue-specific effects (overexpression has known adverse phenotypes) TFAM overexpression caution

1. Scientific importance: TFAM is central to mtDNA maintenance and preventing mtDNA-triggered innate immunity; small-molecule TFAM modulators are novel and potentially powerful chemical probes or starting points for therapeutics targeting mtDNA-leak–driven inflammation (high conceptual novelty).
2. Evidence strength: The cellular evidence is internally consistent (TFAM protein ↑, mtDNA ↑, cytosolic mtDNA ↓, ISG ↓, functional rescue in disease-relevant cells). However, cellular phenotypes do not prove direct TFAM binding or activation; attenuation by TFAM siRNA supports a TFAM-mediated mechanism for some compounds but does not exclude indirect routes (e.g., inhibiting mitochondrial stress pathways upstream of mtDNA release) siRNA attenuation result.
3. Bias and conflict-of-interest: Industry funding (Astellas) and multiple author affiliations with industry create potential sponsor bias. Methods are described sufficiently for in vitro reproducibility, but raw datasets are only available on request which reduces transparency and third-party reanalysis capability.
4. Translational risk: TFAM over-boosting risks hyper-compaction of mtDNA and repression of mitochondrial transcription in vivo; claims about disease-modifying potential require careful dosing windows, tissue-targeting studies, and PK/PD to avoid harm (cited in TFAM overexpression literature) TFAM dosing window caution.

• Biochemical target engagement: measure direct binding of lead compounds to purified TFAM (SPR, ITC, MST) and map binding site (HDX-MS or NMR); test whether compounds alter TFAM DNA-binding affinity (EMSA) or nucleoid compaction in isolated mitochondria.
• Proteome-wide target ID: run CETSA-MS or thermal proteome profiling and/or photoaffinity labeling/chemoproteomics to detect off-targets and explain compound 15 TFAM-independent activity.
• Lon protease axis: test whether compounds block TFAM degradation by Lon (in vitro Lon protease assay and cell-based CHX chase) to evaluate a TMP-like mechanism described previously TMP-Lon-TFAM mechanism.
• In vivo validation: short-term dosing in TFAM-sensitive tissues (kidney, skeletal muscle, brain) with PK/PD, mtDNA copy number, TFAM protein, mt-transcription readouts and assays of inflammation (cGAS/STING markers) to probe efficacy and safety; include heteroplasmic MELAS mouse models if available.
• Therapeutic window: titration in vivo to measure whether modest TFAM increases (~1.2–1.5x) are sufficient for benefit vs. higher levels that produce mtDNA transcriptional repression (guided by Bonekamp et al.) TFAM overexpression limit.

1. Some arylsulfonamide TFAM activators protect TFAM from Lon-mediated degradation by stabilizing TFAM conformation (TMP-like mechanism); biochemical Lon–TFAM turnover assays will confirm this and provide a tractable medicinal-chemistry objective (increase TFAM half-life without hyper-compaction).
2. Compounds that increase TFAM protein without changing TFAM mRNA (as reported) may act by improving mitochondrial import/maturation of TFAM (e.g., altering mitochondrial processing peptidase interactions); test by measuring mitochondrial import kinetics of radiolabeled TFAM precursors ± compound.

• Primary limitation: absence of orthogonal biochemical binding data — falsify main TFAM-binding claim by showing no direct binding of leads to purified TFAM via SPR/ITC and by demonstrating that chemical proteomics identifies alternate primary targets.
• Translatability blindspot: in vitro rescue of MELAS cybrid ATP does not guarantee in vivo rescue of heteroplasmic animals; test in animal models and measure tissue-specific mtDNA heteroplasmy and respiratory chain outputs.
• Safety blindspot: TFAM overexpression literature warns of risks; falsify therapeutic window by dose-escalation in animals showing mitochondrial transcriptional repression at efficacious doses.

This manuscript provides important, well-executed cellular evidence that small molecules can increase TFAM protein and mtDNA copy number and thereby reduce mtDNA-triggered innate immune activation. The data are internally consistent and provide strong chemical-biology leads. However, to upgrade this from a promising preclinical chemical-biology report to a mechanistically proven, translationally credible therapeutic claim, the missing biochemical target engagement, proteome-wide specificity profiling and in vivo efficacy/toxicity studies must be completed.

• Astellas TFAM modulators preprint
• CETSA HTS method
• TMP protects TFAM from degradation
• mtDNA stress activates cGAS-STING

Note: author-review buttons link to BGPT query pages for bespoke author analyses.